How many drug targets are there
作者： John P. Overington , Bissan Al-Lazikani , Andrew L. Hopkins
DOI: 10.1038/NRD2199
关键词: Molecular targets 、 Drug approval 、 Computational biology 、 Drug 、 Medicine 、 Polypharmacology 、 Pharmacology 、 Target protein
摘要: … location: 60% of drug targets are located at the cell surface, compared with only ∼22% of all proteins in the human genome. Despite this strong pattern of membrane association, there …
nature.com
sci-hub.se 参考文章(27)
Dennis Vitkup, Eugene Melamud, John Moult, Chris Sander, Completeness in structural genomics. Nature Structural & Molecular Biology. ,vol. 8, pp. 559- 566 ,(2001) , 10.1038/88640
Eugene V. Koonin, Yuri I. Wolf, Georgy P. Karev, The structure of the protein universe and genome evolution Nature. ,vol. 420, pp. 218- 223 ,(2002) , 10.1038/NATURE01256
Gaia V Paolini, Richard H B Shapland, Willem P van Hoorn, Jonathan S Mason, Andrew L Hopkins, Global mapping of pharmacological space Nature Biotechnology. ,vol. 24, pp. 805- 815 ,(2006) , 10.1038/NBT1228
A HOPKINS, J MASON, J OVERINGTON, Can we rationally design promiscuous drugs Current Opinion in Structural Biology. ,vol. 16, pp. 127- 136 ,(2006) , 10.1016/J.SBI.2006.01.013
Jürgen Drews, Stefan Ryser, Classic drug targets Nature Biotechnology. ,vol. 15, pp. 1350- 1350 ,(1997) , 10.1038/NBT1297-1350
Chanjuan Zheng, Lianyi Han, Chun W. Yap, Bin Xie, Yuzong Chen, Progress and problems in the exploration of therapeutic targets. Drug Discovery Today. ,vol. 11, pp. 412- 420 ,(2006) , 10.1016/J.DRUDIS.2006.03.012
Miles A Fabian, William H Biggs, Daniel K Treiber, Corey E Atteridge, Mihai D Azimioara, Michael G Benedetti, Todd A Carter, Pietro Ciceri, Philip T Edeen, Mark Floyd, Julia M Ford, Margaret Galvin, Jay L Gerlach, Robert M Grotzfeld, Sanna Herrgard, Darren E Insko, Michael A Insko, Andiliy G Lai, Jean-Michel Lélias, Shamal A Mehta, Zdravko V Milanov, Anne Marie Velasco, Lisa M Wodicka, Hitesh K Patel, Patrick P Zarrinkar, David J Lockhart, A small molecule–kinase interaction map for clinical kinase inhibitors Nature Biotechnology. ,vol. 23, pp. 329- 336 ,(2005) , 10.1038/NBT1068
Brian J. Druker, Shu Tamura, Elisabeth Buchdunger, Sayuri Ohno, Gerald M. Segal, Shane Fanning, Jürg Zimmermann, Nicholas B. Lydon, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine. ,vol. 2, pp. 561- 566 ,(1996) , 10.1038/NM0596-561
Jürgen Drews, Stefan Ryser, The role of innovation in drug development. Nature Biotechnology. ,vol. 15, pp. 1318- 1319 ,(1997) , 10.1038/NBT1297-1318
Peter Imming, Christian Sinning, Achim Meyer, Drugs, their targets and the nature and number of drug targets Nature Reviews Drug Discovery. ,vol. 5, pp. 821- 834 ,(2006) , 10.1038/NRD2132